2026-06-10

HY spreads at distress levels — 705bps, recession-associated

HY spreads at distress levels — 705bps, recession-associated

HY spreads at distress levels — 705bps, recession-associated

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) — new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) — new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (PFIZER) — new revenue stream

Phase 3 trial terminated early — JOHNSON The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing El

Phase 3 trial terminated early — JOHNSON Predicting SSRI Efficacy in Veterans With PTSD

Phase 3 trial terminated early — JOHNSON A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Ri

Phase 3 trial terminated early — JOHNSON Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding W

Phase 3 trial terminated early — JOHNSON An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With

Phase 3 trial terminated early — JOHNSON An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With

Phase 3 trial terminated early — JOHNSON An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis

Phase 3 trial terminated early — ELI Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lisp

Phase 3 trial terminated early — ELI A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese

Phase 3 trial terminated early — ELI A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Diseas

Phase 3 trial terminated early — ELI An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Di

Phase 3 trial terminated early — ELI A Study of Evacetrapib in High-Risk Vascular Disease

Phase 3 trial terminated early — ELI A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants

Phase 3 trial terminated early — BRISTOL Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Phase 3 trial terminated early — BRISTOL A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS

Phase 3 trial terminated early — BRISTOL Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular

Phase 3 trial terminated early — BRISTOL A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus N

Phase 3 trial terminated early — BRISTOL A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Ph

Phase 3 trial terminated early — BIOGEN Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Phase 3 trial terminated early — BIOGEN 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3 trial terminated early — BIOGEN A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-St

Phase 3 trial terminated early — BIOGEN A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of

Phase 3 trial terminated early — AMGEN Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarti

Phase 3 trial terminated early — AMGEN Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast C

Phase 3 trial terminated early — REGENERON Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Phase 3 trial terminated early — REGENERON REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate

Phase 3 trial terminated early — REGENERON Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Sever

Phase 3 trial terminated early — REGENERON The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts

Phase 3 trial terminated early — REGENERON Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antib

Phase 3 trial terminated early — REGENERON Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Contin

Phase 3 trial terminated early — REGENERON A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Ant

Phase 3 trial terminated early — REGENERON Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Preve

Phase 3 trial terminated early — Medtronic Minimally Invasive Surgical Therapy for BPH

Phase 3 trial terminated early — Medtronic INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Dis

Phase 3 trial terminated early — Medtronic PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)

Phase 3 trial terminated early — Medtronic Comparison of SCS and PMR in Patients With Refractory Angina Pectoris

Phase 3 trial terminated early — UNITEDHEALTH At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-

Phase 3 trial terminated early — VERTEX A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumac

Phase 3 trial terminated early — VERTEX A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are

Phase 3 trial terminated early — VERTEX Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumat

Phase 3 trial terminated early — VERTEX Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African Amer

Phase 3 trial terminated early — VERTEX Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of A

Phase 3 trial terminated early — VERTEX Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin

Phase 3 trial terminated early — VERTEX A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Thera

Phase 3 trial terminated early — VERTEX A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fib

Phase 3 trial terminated early — VERTEX Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinom

Phase 3 trial terminated early — AbbVie Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine

Phase 3 trial terminated early — AbbVie HCV Test and Treat Utilizing Simplified HCV Patient Education

Phase 3 trial terminated early — AbbVie A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or

Phase 3 trial terminated early — ABBOTT Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Stu

Phase 3 trial terminated early — ABBOTT Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V

Phase 3 trial terminated early — ABBOTT Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakot

Phase 3 trial terminated early — PFIZER Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Phase 3 trial terminated early — PFIZER A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic I

Phase 3 trial terminated early — PFIZER Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Pa

Phase 3 trial terminated early — PFIZER An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures

Phase 3 trial terminated early — PFIZER Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

Phase 3 trial terminated early — PFIZER A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anx

Phase 3 trial terminated early — PFIZER A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Phase 3 trial terminated early — Merck A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Jo

Phase 3 trial terminated early — Merck Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Phase 3 trial terminated early — Merck A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f®

Phase 3 trial terminated early — Merck Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Phase 3 trial terminated early — Merck MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Phase 3 trial terminated early — Merck A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINAT

Phase 3 trial terminated early — Merck MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibi

Phase 3 trial terminated early — GILEAD Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B

Phase 3 trial terminated early — GILEAD The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomona

Phase 3 trial terminated early — GILEAD The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertensi

Phase 3 trial terminated early — GILEAD Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 3 trial terminated early — GILEAD Botswana Tenofovir Oral HIV Prophylaxis Trial

Phase 3 trial terminated early — GILEAD Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Phase 3 trial terminated early — GILEAD Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Phase 3 trial terminated early — GILEAD ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifunga

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves RIFABUTIN (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves RIFABUTIN (PFIZER) — new revenue stream

FDA approves RIFABUTIN (PFIZER) — new revenue stream

Missed consensus by 8.9% — EPS $0.07 vs $0.0768 estimate

Beat consensus by 59.7% — EPS $-0.15 vs $-0.3723 estimate

Beat consensus by 22.0% — EPS $2.57 vs $2.1063 estimate

Beat consensus by 6.1% — EPS $1.90099 vs $1.7915 estimate

Missed consensus by 134.4% — EPS $-0.04 vs $0.1163 estimate

Missed consensus by 22.8% — EPS $0.1 vs $0.1295 estimate

Missed consensus by 98.2% — EPS $0.002 vs $0.1117 estimate

Beat consensus by 41.0% — EPS $-0.13 vs $-0.2203 estimate

Beat consensus by 14.2% — EPS $0.5 vs $0.4379 estimate

Missed consensus by 6.3% — EPS $0.56 vs $0.5978 estimate

Missed consensus by 7.8% — EPS $0.61 vs $0.6616 estimate

Missed consensus by 9.5% — EPS $0.52 vs $0.5743 estimate

Missed consensus by 25.4% — EPS $4.23 vs $5.6712 estimate

Beat consensus by 202.5% — EPS $3.33 vs $1.1009 estimate

Missed consensus by 95.8% — EPS $0.1 vs $2.3533 estimate

Missed consensus by 12.9% — EPS $0.7 vs $0.8033 estimate

Missed consensus by 78.1% — EPS $0.16 vs $0.7319 estimate

Beat consensus by 63.5% — EPS $0.85712 vs $0.5242 estimate

Beat consensus by 82.9% — EPS $0.61282 vs $0.3351 estimate

Beat consensus by 79.8% — EPS $0.60506 vs $0.3365 estimate

Missed consensus by 5.3% — EPS $0.16 vs $0.169 estimate

Missed consensus by 37.6% — EPS $0.11 vs $0.1763 estimate

Missed consensus by 51.7% — EPS $0.09 vs $0.1865 estimate

Beat consensus by 51.3% — EPS $0.27 vs $0.1785 estimate

Beat consensus by 6.9% — EPS $0.68 vs $0.6363 estimate

Missed consensus by 6.6% — EPS $0.67 vs $0.7171 estimate

Missed consensus by 31.1% — EPS $0.64 vs $0.9292 estimate

Beat consensus by 26.8% — EPS $1.46 vs $1.1514 estimate

Missed consensus by 8.2% — EPS $-0.59 vs $-0.5454 estimate

Beat consensus by 37.0% — EPS $-0.35 vs $-0.5555 estimate

Beat consensus by 208.1% — EPS $0.33 vs $0.1071 estimate

Beat consensus by 85.4% — EPS $0.104 vs $0.0561 estimate

Missed consensus by 41.2% — EPS $0.03 vs $0.051 estimate

Missed consensus by 39.3% — EPS $0.28 vs $0.461 estimate

Beat consensus by 92.6% — EPS $0.11 vs $0.0571 estimate

Beat consensus by 24.1% — EPS $0.56 vs $0.4514 estimate

Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Beat consensus by 6.3% — EPS $0.44 vs $0.4141 estimate

Beat consensus by 14.9% — EPS $0.55 vs $0.4787 estimate

Beat consensus by 98.1% — EPS $-0.02 vs $-1.0532 estimate

Beat consensus by 131.6% — EPS $0.28 vs $-0.8874 estimate

Beat consensus by 713.9% — EPS $1.55 vs $-0.2525 estimate

Missed consensus by 247.6% — EPS $-0.39 vs $-0.1122 estimate

Missed consensus by 96.1% — EPS $-5.4 vs $-2.754 estimate

Missed consensus by 43.3% — EPS $-0.19 vs $-0.1326 estimate

Beat consensus by 8.9% — EPS $0.6 vs $0.5508 estimate

Beat consensus by 12.7% — EPS $0.69 vs $0.612 estimate

Missed consensus by 36.9% — EPS $-4.47 vs $-3.264 estimate

Beat consensus by 7.7% — EPS $-3.2 vs $-3.468 estimate

Missed consensus by 17.6% — EPS $-4.32 vs $-3.672 estimate

Missed consensus by 22.5% — EPS $-4 vs $-3.264 estimate

Missed consensus by 60.8% — EPS $57.6 vs $146.88 estimate

Beat consensus by 100.0% — EPS $0 vs $-0.0068 estimate

Missed consensus by 4268.6% — EPS $-7.37 vs $0.1768 estimate

Missed consensus by 76.5% — EPS $0.62 vs $2.6418 estimate

Beat consensus by 780.7% — EPS $1.27 vs $0.1442 estimate

Missed consensus by 81.7% — EPS $0.02 vs $0.1091 estimate

Missed consensus by 10258.9% — EPS $-4.33 vs $-0.0418 estimate

Beat consensus by 5.4% — EPS $0.62 vs $0.5885 estimate

Missed consensus by 13.5% — EPS $0.44 vs $0.5088 estimate

Beat consensus by 13.5% — EPS $0.52 vs $0.458 estimate

Beat consensus by 20.4% — EPS $0.52 vs $0.4318 estimate

Beat consensus by 8.0% — EPS $0.12 vs $0.1111 estimate

Missed consensus by 85.3% — EPS $0.02 vs $0.1364 estimate

Beat consensus by 15.5% — EPS $0.14 vs $0.1212 estimate

Beat consensus by 11.1% — EPS $0.11 vs $0.099 estimate

Missed consensus by 387.7% — EPS $-11.96 vs $-2.4521 estimate

Beat consensus by 9.5% — EPS $1.51 vs $1.379 estimate

Missed consensus by 205.4% — EPS $-3.09 vs $2.9325 estimate

Beat consensus by 1677.4% — EPS $22.48 vs $1.2648 estimate

Missed consensus by 10.3% — EPS $3.47 vs $3.8682 estimate

Beat consensus by 16.5% — EPS $0.12 vs $0.103 estimate

Beat consensus by 61.8% — EPS $0.05 vs $0.0309 estimate

Missed consensus by 86.1% — EPS $0.01 vs $0.0721 estimate

Beat consensus by 6.8% — EPS $0.2 vs $0.1873 estimate

Beat consensus by 40.1% — EPS $0.28 vs $0.1998 estimate

Oil +5.86% — significant rally

Gold -4.33% — significant selloff

OSINT: Valencian teachers pause strike, reject salary hike offer

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Gold -2.63% — significant selloff

OSINT: US Defense Leaders Visit Guantanamo Bay aboard CH-47F Chinook

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

OSINT: Ukrainian FP-5 Flamingo Cruise Missile Flies 1,000 km into Russian Airspace

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC CRUDE OIL WTI speculator at extreme short — contrarian bull signal

OSINT: US questions and bars World Cup players, staff entry despite FIFA

ETH ETF inflow of $178M — institutional buying

BTC ETF inflow of $2266M — institutional buying

BTC open interest -46.8% — OI collapse

ETH open interest -60.4% — OI collapse

SOL open interest +258.5% — OI surge

BTC ETF inflow of $2266M — institutional buying

ETH ETF inflow of $178M — institutional buying

ETH open interest +222.7% — OI surge

SOL open interest +247.7% — OI surge

BTC open interest +234.6% — OI surge

SOL open interest +257.3% — OI surge

ETH open interest +230.6% — OI surge

BTC open interest +232.0% — OI surge

BTC open interest +230.0% — OI surge

ETH open interest -25.0% — OI collapse

SOL open interest +261.8% — OI surge